Erasca, Inc. (ERAS)
NASDAQ: ERAS · Real-Time Price · USD
1.450
-0.070 (-4.61%)
Jul 11, 2025, 4:00 PM - Market closed
Erasca Employees
Erasca had 103 employees as of December 31, 2024. The number of employees decreased by 23 or -18.25% compared to the previous year.
Employees
103
Change (1Y)
-23
Growth (1Y)
-18.25%
Revenue / Employee
n/a
Profits / Employee
-$1,530,087
Market Cap
410.77M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 103 | -23 | -18.25% |
| Dec 31, 2023 | 126 | -3 | -2.33% |
| Dec 31, 2022 | 129 | 6 | 4.88% |
| Dec 31, 2021 | 123 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ERAS News
- 5 weeks ago - Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001 - GlobeNewsWire
- 6 weeks ago - Erasca to Present at Upcoming Investor Conferences in June - GlobeNewsWire
- 2 months ago - Erasca Reports First Quarter 2025 Business Updates and Financial Results - GlobeNewsWire
- 2 months ago - Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway - GlobeNewsWire
- 2 months ago - Erasca to Present at the Bank of America Securities Health Care Conference - GlobeNewsWire
- 2 months ago - Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting - GlobeNewsWire
- 2 months ago - Erasca, Inc.: Carving A Different Niche In RAS Signaling - Seeking Alpha
- 3 months ago - Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting - GlobeNewsWire